Lapatinib and erlotinib are potent reversal agents for MRP7(ABCC10)-mediated multidrug resistance

In recent years, a number of TKIs (tyrosine kinase inhibitors) targeting epidermal growth factor receptor (EGFR) family have been synthesized and some have been approved for clinical treatment of cancer by the FDA. We recently reported a new pharmacological action of the 4-anilinoquinazoline derived...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Kuang, Ye-Hong, Shen, Tong, Chen, Xiang, Sodani, Kamlesh, Hopper-Borge, Elizabeth, Tiwari, Amit Kumar, Lee, Jeferson W K K, Fu, Li-Wu, Chen, Zhe-Sheng
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2009
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2953260/
https://ncbi.nlm.nih.gov/pubmed/19720054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2009.08.021
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak